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ess: unsalebru73@yahoSummary Objective: Insulin like growth factor 1 (IGF-1) is recognized as a potent
mitogen for many cancer cell lines and there is good evidence that lung cancer cells
produce both IGF-1 and insulin like growth factor binding protein 3 (IGFBP-3). The
aim of this study was to investigate the clinical significance of IGF-1 and IGFBP-3
levels in serum and in bronchoalveolar lavage (BAL) fluid by comparing lung cancer
patients with healthy controls.
Methods: BAL fluid and serum samples were obtained from 24 lung cancer
patients and 12 healthy controls, and were analyzed for IGF-1 and IGFBP-3 levels by
a two site immunoradiometric assay. The recovered BAL fluid was standardized by
albumin to remove the variable of dilution and the data was expressed in epithelial
lining fluid (ELF).
Results: Serum IGF-1 and IGFBP-3 levels were lower in lung cancer patients, but
the difference between the groups did not reach a statistical significance. IGF-1/
IGFBP-3 ratio in ELF was significantly lower in lung cancer patients (P ¼ 0:035). Mean
IGF-1 level in ELF was determined to be significantly lower in patients with distant
metastasis (P ¼ 0:04). Serum IGF-1/IGFBP-3 ratio was found to be significantly lower
in patients with distant (P ¼ 0:04) and nodal metastasis (P ¼ 0:03). Tumor stage was
negatively correlated with IGF-1 level in ELF (P ¼ 0:05; r ¼ 0:4) and serum IGF-1/
IGFBP-3 ratio (P ¼ 0:04; r ¼ 0:4).
Conclusion: IGF-1 and IGFBP-3 levels both in serum and ELF might serve a clinical
significance in patients with lung cancer. However, further studies comprising moreElsevier Ltd. All rights reserved.
No: 16/8, Y. Ayrancy´, 06550. Tel.: +90 312 428 06 13; fax: +90 312 355 21 35.
o.com (E. U¨nsal).
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& 2004 Elsevier Ltd. All rights reserved.Introduction
Insulin like growth factors (IGFs) are important
mitogens acting as endocrine, paracrine and auto-
crine agents.1,2 They are present in most of the
biological fluids and carried by specific binding
proteins (IGFBPs). The major form of binding
protein known in human circulation is IGFBP-3,
which modulates IGF activity and also regulates cell
growth and apoptosis.1,3 IGF-1 is recognized as a
potent mitogen for many cancer cell lines and plays
an important role in neoplastic transformation.1–5
In the recent epidemiologic studies, the association
between IGFs and prostate cancer, breast cancer,
colorectal cancer and also lung cancer has been
demonstrated.2,6–9
There is a good evidence that lung cancer cells
produce both IGF-1 and IGFBP-3 and the circulating
levels of IGF-1 and IGFBP-3 may be important in
determining the risk of lung cancer.5,9 Also,
previous studies have examined the serum levels
of IGF-1 and IGFBP-3 in lung cancer patients and
the relationship with the stage of disease and
histopathologic type.10,11 This is the first study
investigating the clinical significance of IGF-1 and
IGFBP-3 levels in serum and in bronchoalveolar
lavage (BAL) fluid by comparing lung cancer
patients with healthy controls.Materials and methods
Patients
The study was conducted on 36 subjects who were
divided into two groups. Group 1 consisted of 24
lung cancer patients. The diagnosis of malignancy
was confirmed by bronchial lavage, sputum cytol-
ogy or tissue biopsy specimens. Group 2 consisted
of 12 control subjects who had undergone fiber-
optic bronchoscopy (FOB) for various reasons (7 for
hemoptysis work up, 5 for non-productive cough)
and no pathologic finding could be reached even-
tually.
Patients with the diseases affecting the serum
levels of IGF-1 such as inflammatory bowel dis-
eases, chronic liver disease, renal failure, hepato-
cellular carcinoma and interstitial lung disease
were excluded from the study. Women receiving
hormone replacement therapy were also notcandidates for our study since hormone replace-
ment therapy increases serum IGF-1 levels. The
study was approved by the Local Ethics Committee
of Atatu¨rk Chest Diseases and Chest Surgery
Research Hospital and informed consent was
obtained from all the subjects enrolled in the study.FOB and BAL
A patient with a pulmonary mass lesion was a
candidate for our study. At the time of diagnostic
bronchoscopy we collected BAL from lobar or
segmental bronchus of the disease side. The
patients with endobronchial lesions occluding the
bronchus and hemorrhagic BAL were excluded from
the study.
All subjects were premedicated subcutaneously
with atropine (0.5mg) and intramuscular diazepam
(5mg). The upper respiratory tract was anesthe-
tized topically with 2% prilocaine via an ultrasonic
nebulizer. Bronchoscopy was performed with a
flexible FOB. BAL was accomplished through the
FOB by instillation of sterile 0.9% saline solution
(three times 50ml aliquots) into the bronchoalveo-
lar tree, bronchus of the disease side in lung cancer
patients, right middle lobe or lingula in control
subjects.
The BAL fluid was retrieved immediately with
‘zero dwell time’ by gentle suctioning. The mean
recovery of the injected fluid was similar in groups
1 and 2 and found to be 31711.3% and 33.577.6%,
respectively. The collected fluid filtered through
three layers of sterile gauze and then centrifuged
at 800 rpm for 10min. After centrifuging the
supernatant was divided into two, one for IGF-1,
IGFBP-3 and one for albumin determination and
stored at –40 1C for later analysis.Blood samples
As there is a circadian rhythm of IGF-1 secretion,
we collected the blood samples from each case
between 9:00 and 10:00 o’clock in the morning, the
day after the bronchoscopy. Ten milliliter of venous
blood sample was drawn from every patient,
centrifuged immediately at 1500 rpm for 10min.
The serum was divided into two, one for IGF-1,
IGFBP-3 and one for albumin determination and
stored at 40 1C for later analysis.
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in BAL and serum
IGF-1 levels were measured in BAL and serum with
DSL-5600 ACTIVE IGF-1 Coated Tube IRMA Kit
(Diagnostic Systems Laboratories, Webster, Texas,
USA), which includes acid-ethanol extraction step
to separate IGF-1 from its binding protein. The
procedure employed a two site immunoradiometric
assay (IRMA) principle first described by Milles
et al.12 IGFBP-3 levels were measured with DSL-
6600 ACTIVE IGFBP-3 Coated Tube IRMA Kit (Diag-
nostic Systems Laboratories, Webster, Texas, USA).
The IRMA is a non-competitive assay in which the
analyte to be measured is ‘sandwiched’ between
two antibodies. The first antibody is immobilized to
the inside wall of the tubes, the other antibody is
radiolabeled for detection. BAL and serum albumin
levels were measured by Beckman Coulter Syn-
chron LX20 Oto Analyzer by the Bromkresolpurpur
(BCP) colorimetry method.
Standardization of BAL fluid
The technique of BAL is based on the concept that
aliquots of sterile saline solution infused through
the bronchoscope mix with epithelial lining fluid
(ELF). Since the recovered BAL fluid is a variable
mixture of saline solution, ELF and ELF compo-
nents, it has been difficult to estimate the actual
concentration of recovered molecules in the ELF in
situ. The standardization method removes the
variable of dilution and allows comparison between
data in different subjects and from different
investigations. Standardization of IGF-1 and
IGFBP-3 levels in BAL fluid with the corresponding
albumin levels was done using the following
formulas:13(1)T
V
S
M
S
B
G
*ELFvolume=(BALalbumin BALvolume)/Serumalbumin.
(2) ELF substance=(BALvolumeBAL substance)/
ELFvolume.
(3) ELF substance=(BAL substance Serumalbumin)/
BALalbumin.able 1 The sex distribution, mean ages, smoking histo
ariable Group 1 (n ¼
ex (male/female) 21 M/3 F
ean ages (years) 6079
moking history (pack-years) 56745
ody mass index (kg/m2) 23.471.7
roup 1: lung cancer patients, Group 2: control subjects.
Statistically significant.Statistical analysis
Statistical analysis was carried out using SPSS
program version 10.0. Results were expressed as
mean7SD. Differences between groups were eval-
uated by using the Mann Whitney U-test and
differences in gender between groups were exam-
ined by w2-test. The Spearman rank correlation
coefficient test was used to examine the associa-
tion between variables. Any P value less than
or equal to 0.05 was considered statistically
significant.Results
The sex distribution, mean ages, smoking history
and body mass indexes of groups 1 and 2 are listed
in Table 1. Group 1 consisted of 21 males and 3
females with a mean age of 6079 years. Group 2
consisted of 11 males and 1 female with a mean age
of 43711 years. Mean smoking history of groups 1
and 2 were 56745 and 48720 pack-years, respec-
tively. Mean body mass indexes of groups 1 and 2
were 23.471.7 and 23.671.6 kg/m2, respectively.
The two groups were similar in sex, smoking history
and body mass indexes, but group 2 was younger
than group 1 (P ¼ 0:0). The histological diagnosis 24
lung cancer patients were 8 adenocarcinoma, 7
small cell carcinoma, 4 non-small cell carcinoma, 3
squamous cell carcinoma, 1 adenosquamous carci-
noma, and 1 malign epithelial carcinoma. Tumor
(T), node (N), metastasis (M) stages, localizations
and mean tumor diameter of group 1 patients are
listed in Table 2.
IGF-1, IGFBP-3 levels and IGF-1/IGFBP-3 ratios in
serum and ELF of both groups are listed in Table 3.
Serum levels of IGF-1 and IGFBP-3 were 126.97
63.4 and 2277.67614.0 ng/ml, respectively, in
group 1 and 167.6756.5 and 2874.77861.9 ng/
ml, respectively, in group 2. Serum IGF-1 and
IGFBP-3 levels were lower in lung cancer patients,
but the difference between the groups did notry and body mass indexes of the study groups.
24) Group 2 (n ¼ 12) P
11 M/1 F 1.0
43711 0.0*
48720 0.5
23.671.6 0.6
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and IGFBP-3 were 3157.673919.0 and 1272.07
680.1 ng/ml, respectively, in group 1 and 4456.87
4850.8 and 1048.57867.5 ng/ml, respectively, in
group 2. ELF levels of IGF-1 and IGFBP-3 were not
statistically different between the groups. IGF-1/
IGFBP-3 ratio in ELF was significantly lower in group
1 (2.873.8) than in group 2 (5.176.5) (P ¼ 0:035),
whereas serum IGF-1/IGFBP-3 ratio was not statis-
tically different between the two groups (0.057
0.02 vs. 0.0670.02) (P40:05). Median and inter-
quartile range of serum and ELF IGF-1, IGFBP-3
levels and IGF-1/IGFBP-3 ratios in groups 1 and 2
are shown in Fig. 1.
The relationship of clinicopathologic features
with IGF-1, IGFBP-3 levels and IGF-1/IGFBP-3 ratios
in serum and ELF of lung cancer patients is shown in
Table 4. When the patients were grouped on theTable 2 Tumor (T), node (N), metastasis (M)
stages, localizations and mean tumor diameter of
group 1 patients.
Variables Data
T1 1 (4.2%)
T2 5 (20.8%)
T3 7 (29.2%)
T4 11 (45.8%)
N0 7 (29.2%)
N1 2 (8.3%)
N2 7 (29.2%)
N3 8 (33.3%)
M0 11 (45.8%)
M1 13 (54.2%)
Stage 1B 1 (4.2%)
Stage 2B 2 (8.3%)
Stage 3A 3 (12.5%)
Stage 3B 5 (20.8%)
Stage 4 13 (54.2%)
Central localization 13 (54.2%)
Peripheric localization 11 (45.8%)
Mean tumor diameter 6.072.0 l cm (min
2 cm–max 10 cm)
Table 3 IGF-1, IGFBP-3 levels and IGF-1/IGFBP-3 ratios
Variable Group 1
Serum IGF-1 (ng/ml) 126.9763.4 (95% CI: 100.1–153.7)
Serum IGFBP-3 (ng/ml) 2277.67614.0 (95% CI: 2018.1–25
Serum IGF-1/IGFBP-3 0.0570.02 (95% CI: 0.045–0.062)
ELF IGF-1 (ng/ml) 3157.673119.0 (95% CI: 1502.7–4
ELF IGFBP-3 (ng/ml) 1272.07680.1 (95% CI: 984.8–155
ELF IGF-1/IGFBP-3 2.873.8 (95% CI: 1.2–4.4)
Group 1: lung cancer patients, Group 2: control subjects.
*Statistically significant.basis of tumor diameter (greater than 5 and smaller
than 6 cm), histological type (non-small cell lung
cancer and small cell lung cancer), and localization
of tumor (central and peripheric), there was no
significant difference between the groups for IGF-1,
IGFBP-3 levels and IGF-1/IGFBP-3 ratios in serum
and ELF (P40:05). When the lung cancer patients
were grouped based on the presence of distant
metastasis, IGF-1 level in ELF was determined to be
significantly lower in patients with distant metas-
tasis (P ¼ 0:04). Serum IGF-1/IGFBP-3 ratio was
found to be significantly lower in patients with
distant metastasis (P ¼ 0:04) and nodal metastasis
(P ¼ 0:03).
The correlations between the tumor diameter
(cm), stages (1–4) and IGF-1, IGFBP-3 levels and
IGF-1/IGFBP-3 ratios in serum and ELF are listed in
Table 5. Tumor stage was negatively correlated
with IGF-1 level in ELF (P ¼ 0:05; r ¼ 0:4) and
serum IGF-1/IGFBP-3 ratio (P ¼ 0:04; r ¼ 0:4).Discussion
Immunoreactive IGF-1 is produced in vitro by
human fetal lung explants and cultured alveolar
macrophages. IGF-1 is detectable in primary lung
tumor tissue at higher levels than in normal lung
tissue. Thus, lung cancer cells synthesize both IGF-
1 and IGFBP-3 which appear to be important factors
in neoplastic transformation and metastasis.1,5
As tissue IGF bioactivity appears to be regulated
in parallel with circulating IGF-1 level, there is a
hypothesis that circulating levels of IGF-1 and
IGFBP-3 may be important in determining risk of
lung cancer.2,14 Yu et al. examined 208 lung cancer
patients and 218 control subjects in a case control
study and they found high plasma level of IGF-1 and
low plasma level of IGFBP-3 associated with
increased risk of lung cancer.9 However, in another
case control study, London et al. found no associa-
tion between serum IGF-1 level and lung cancerin serum and ELF of the study groups.
Group 2 P
167.6756.5 (95% CI: 131.7–203.6) 0.07
36.9) 2874.77861.9 (95% CI: 2327–3422.3) 0.06
0.0670.02 (95% CI: 0.048–0.073) 0.2
812.5) 4456.874850.8 (95% CI: 1374.8–7538.9) 0.2
9.1) 1048.57867.5 (95% CI: 497.3–1599.7) 0.2
5.176.5 (95% CI: 0.9–9.2) 0.035*
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Figure 1 Median and interquartile range of serum and ELF IGF-1, IGFBP-3 levels and IGF-1/IGFBP-3 ratios in groups 1
and 2.
IGF-1 and IGFBP-3 levels in BAL and serum of lung cancer patients 563risk; they reported only high serum level of IGFBP-3
associated with reduced risk of lung cancer.15
IGFs are present in most of the biological fluids.
Olchovsky et al. examined IGFs and IGFBPs levels in
pleural effusion with different etiologies and IGF-1
and IGFBP-2 levels were found elevated in the
group with malignant tumors. They suggested thatthere is a local production of IGF-1 by tumor cells
and reported IGF-1 to be used in assessment of
pleural effusion as a tumor marker.16 To our
knowledge, this is the first study investigating the
clinical significance of IGF-1 and IGFBP-3 levels
both in BAL fluid and serum of lung cancer patients
by comparing them with healthy controls.
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Table 4 The relationship of clinicopathologic features with IGF-1, IGFBP-3 levels and IGF-1/IGFBP-3 ratios in
serum and ELF of lung cancer patients.
Variables Serum ELF
IGF-1
(ng/ml)
IGFBP-3
(ng/ml)
IGF-1/
IGFBP-3
IGF-1
(ng/ml)
IGFBP-3
(ng/ml)
IGF-1/
IGFBP-3
T. diameter
45 cm (n ¼ 10) 115.7762.8 2128.77592.4 0.05270.019 3480.275562.7 1240.27790.6 3.174.9
o5 cm (n ¼ 11) 119.9763.4 2260.27641.1 0.05370.023 2776.771984.4 1161.27621.2 2.873.1
P 0.7 0.8 0.8 0.4 0.9 0.6
N0,1 (n ¼ 9) 150.8744.5 2376.07645.5 0.06570.016 4202.975579.0 1309.17795.0 3.574.9
N2,3 (n ¼ 15) 112.5770.0 2218.67609.4 0.04870.021 2530.472514.4 1249.77630.2 2.473.0
P 0.09 0.6 0.03* 0.5 1.0 0.6
M0 (n ¼ 11) 150.7760.5 2356.87577.5 0.06370.016 4417.574480.8 1474.27652.2 4.175.0
M1 (n ¼ 13) 106.7760.8 2210.77658.9 0.04770.021 2091.672626.7 1100.87680.3 1.771.9
P 0.055 0.6 0.04* 0.04* 0.1 0.1
NSCLC (n ¼ 16) 134753.7 2381.37611.1 0.05770.018 328874469.6 1382.97701.3 2.674.0
SCLC (n ¼ 7) 106.6786.5 1975.37584.5 0.04870.027 2872.772964.8 1040.47666.3 3.173.8
P 0.2 0.1 0.3 0.8 0.2 0.5
Central (n ¼ 13) 110.7756.7 2245.47673.2 0.04870.016 4316.274938.2 1243.47697.0 3.974.7
Peripheric (n ¼ 11) 145.9768.3 2315.87566.0 0.06270.023 1788.471501.5 1305.77691.7 1.571.4
P 0.2 0.8 0.06 0.2 0.9 0.1
T: tumor, N: nodal metastasis, M: distant metastasis, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer.
*Statistically significant.
Table 5 The correlations between the tumor
diameter (cm), stages (1,2,3,4) and IGF-1, IGFBP-3
levels and IGF-1/IGFBP-3 ratios in serum and ELF.
Variables Tumor
diameter
(cm)
Stages
(1–4)
Serum IGF-1 (ng/ml) r ¼ 0:02 r ¼ 0:39
P ¼ 0:9 P ¼ 0:058
Serum IGFBP-3 (ng/ml) r ¼ 0:13 r ¼ 0:13
P ¼ 0:5 P ¼ 0:5
Serum IGF-1/IGFBP-3 r ¼ 0:1 r ¼ 0:4
P ¼ 0:5 P ¼ 0:04*
ELF IGF-1 (ng/ml) r ¼ 0:05 r ¼ 0:4
P ¼ 0:8 P ¼ 0:05*
ELF IGFBP-3 (ng/ml) r ¼ 0:005 r ¼ 0:3
P ¼ 0:3 P ¼ 0:06
ELF IGF-1/IGFBP-3 r ¼ 0:07 r ¼ 0:2
P ¼ 0:7 P ¼ 0:2
*Statistically significant.
E. U¨nsal et al.564In previous studies IGF-1 levels were found to be
reduced in serum of lung cancer patients which
might be due to poor nutritional status or abnormal
liver function.10,11 In our study, serum IGF-1 and
IGFBP-3 levels were found to be lower in lung
cancer patients, but the difference between thegroups did not reach a statistical significance. It is
known that serum levels of IGF-1 and IGFBP-3
depend on age, smoking history and nutritional
status.17,18 In our study, two groups were similar
in smoking history and body mass indexes. Both
groups had a mean age over 40 years, but because
of the difficulty in finding elder healthy controls,
there was a statistically significant difference
between the groups in age. The control group was
younger than the lung cancer group. So, here it is
important to recall that the difference might be
due to the difference of mean ages between the
groups.
IGFs system has been reported to play an
important role in chronic interstitial fibrotic dis-
eases and increased levels of IGF-1 and IGFBP-3
have been reported in the BAL fluid of patients with
idiopathic pulmonary fibrosis.19–21 But less is known
about IGF/IGFBP system in BAL fluid of lung cancer
patients. In our study, we did not find significant
differences between lung cancer patients and the
healthy controls for both IGF-1 and IGFBP-3 levels
in ELF. On the other hand, IGF-1/IGFBP-3 ratio in
ELF was found to be significantly lower in lung
cancer patients. The alterations in IGF-1/IGFBP-3
balance have been shown to play a role in
carcinogenesis.4 Our results might be due to the
interaction between IGF-1 and IGFBP-3.
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growth hormone (GH) and altered regulation of
GH/IGF-1 system has been reported to play a role in
the progression of lung cancer. Mazzoccoli et al.
found that serum IGF-1 levels were lower in cancer
patients, especially in advanced stages of the
disease.10 In our study, IGF-1 levels in ELF were
significantly lower in lung cancer patients with
distant metastasis. Also, a negative correlation was
found between IGF-1 levels in ELF and the stage of
the disease. This might be due to the reduced
synthesis of IGF-1 in the liver especially in
advanced stage of the disease.
Serum IGF-1/IGFBP-3 ratio was significantly low-
er in lung cancer patients with nodal and distant
metastasis. Although IGF-1/IGFBP-3 ratio in ELF did
not show any significant correlation with the stage
of lung cancer, IGF-1/IGFBP-3 ratio in serum was
found to be negatively correlated with the stage. It
has been known that IGFBP-3 regulates IGF-1
activity and also cell growth and apoptosis.1,3
There is a negative correlation between serum
IGFBP-3 levels and prostate, lung, colon cancer risk
and this suggests a protective role of IGFBP-3
against the effects of systemic IGF-1.4,9 Thus, in
lung cancer the balance between IGF-1and IGFBP-3
might be important in the progression of the
disease. The mechanism of this is unclear and it
should be investigated by further studies.
Lee et al. found that serum IGF-1 levels were
lower in NSCLC patients than in the SCLC group.
They reported that serum levels of IGF-1 and
IGFBPs might be useful markers for diagnosing and
identifying tumor types in lung cancer.11 In contrast
to this finding, we did not find any significant
relationship between IGF-1, IGFBP-3 levels and
histopathologic type both in serum and ELF. Also
there was no relation between the tumor localiza-
tion, diameter and IGF-1, IGFBP-3 levels in serum
and ELF.
As a conclusion, analysis of IGF-1 and IGFBP-3
levels both in serum and ELF might serve a
diagnostic value in lung cancer patients especially
in the advanced stage of the disease. However,
further studies comprising more cases are needed
to investigate the clinical significance of IGF-1 and
IGFBP-3 in lung cancer.References
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